Pyxis Oncology Completed The Sale Of Its Rights To Royalties From The Commercialization Of Beovu (Brolucizumab-dbll) And Another Asset To Novartis For $8M
Pyxis Oncology以800萬美元的價格向諾華完成了向諾華出售其從Beovu(brolucizumab-DBLL)商業化中獲得的特許權使用費和另一項資產
Pyxis Oncology Completed The Sale Of Its Rights To Royalties From The Commercialization Of Beovu (Brolucizumab-dbll) And Another Asset To Novartis For $8M
Pyxis Oncology以800萬美元的價格向諾華完成了向諾華出售其從Beovu(brolucizumab-DBLL)商業化中獲得的特許權使用費和另一項資產
使用瀏覽器的分享功能,分享給你的好友吧